UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

Triaging individuals with the highest likelihood of cancer detection with their clinical indication and individual risk factors during periods of reduced capacity could be an efficient way of identifying the most cancers with the least examinations compared with a non–risk-based approach.

Experts from Northern California-based cancer center to join panels responsible for evidence- based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.

Mehrdad Abedi, MD, discusses the challenges of standard transplant, how Orca-T could overcome some of those limitations, and the potential future of transplant in hematologic malignancies.

The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.

R. Lor Randall, MD, discusses the intriguing risk-stratification–based trial in NSTRS and how the findings can be used to guide treatment decisions in this pediatric population.

R. Lor Randall, MD, FACS, discusses the rationale and motivation behind tissue-engineered platforms and how they could significantly impact the understanding of how cancer arises in or metastasizes to bone. 

R. Lor Randall, MD, FACS, discusses the concept and prospect of up-front resection in osteosarcoma from the Osteosarcoma Collaborative.

R. Lor Randall, MD, FACS, discusses limb salvage surgeries that have been made possible through 3D printing, and the technological advances that are helping to increase precision and turnaround times.

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

R. Lor Randall, MD, FACS, highlights the various data presented at the annual MSTS meeting and their implications for the future of sarcoma treatment.

In our exclusive interview, David R. Gandara, MD highlights the benefits and challenges of delivering patient care virtually and its reception among patients, discusses the sustainability of virtual CME platforms and forecasts what the “new normal” of oncology education may look like as a result of the pandemic.

R. Lor Randall, MD, highlights the innovative efforts by the COG, ongoing studies in sarcomas, and how the organization is adapting during a world with COVID-19.

Premenopausal women with breast cancer who were previously treated with radiotherapy for a primary childhood, adolescent, or young adult cancer were found to have worse breast cancer–specific survival.

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer.

R. Lor Randall, MD, FACS, discusses current approaches in the surgical management of patients with osteosarcoma that has metastasized to the lungs.

Karen Kelly, MD, discusses challenges with choosing when to start immunotherapy in patients with lung cancer.

R. Lor Randall, MD, FACS, highlights the specific challenges faced by adolescent and young adult patients with sarcomas, the importance of promoting awareness of this issue, and the resources available to improve outcomes in this population.

R. Lor Randall, MD, FACS, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.

R. Lor Randall, MD, discusses the referral challenges for orthopedic oncologists and the importance of improving quality of life for patients with metastatic bone disease.

R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.

Jonathan Riess, MD, MS, discusses ongoing research with PARP inhibitors in lung cancer and potential biomarkers for this class of agents.

Richard Bold, MD, chief of the Division of Surgical Oncology, has been named Physician-in-Chief of the UC Davis Comprehensive Cancer Center.

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.

Advances in treatment and supportive care have resulted in substantial improvements in cancer survival and a growing number of cancer survivors in the United States.

Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.

Clinical trial designs are transforming dramatically in order to expedite the discovery and validation of new predictive biomarkers for patients with non–small cell lung cancer and other types of solid tumors.

Thomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.

Moon S. Chen Jr., PhD, MPH, associate director, Population Research and Cancer Disparities, professor, UC Davis Comprehensive Cancer Center, discusses various disparities in cancer care in underserved populations.